{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:26:37Z","timestamp":1761513997427,"version":"3.41.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ygyno.2017.04.013","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T14:19:01Z","timestamp":1493129941000},"page":"205-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Managing hereditary breast cancer risk in women with and without ovarian cancer"],"prefix":"10.1016","volume":"146","author":[{"given":"Mary Linton","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy E.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.04.013_bb0005","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"year":"2016","author":"Network NCC","series-title":"Genetic\/Familial High-Risk Assessment: Breast and Ovarian","key":"10.1016\/j.ygyno.2017.04.013_bb0010"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0015","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0025","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0030","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/AOG.0b013e3181a106d4","volume":"113","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/M13-2747","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bjc.2013.730","article-title":"BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface","volume":"110","author":"Lee","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0050","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1200\/JCO.2002.05.121","article-title":"BRCAPRO validation, sensitivity of genetic testing of BRCA1\/BRCA2, and prevalence of other breast cancer susceptibility genes","volume":"20","author":"Berry","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0055","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0065","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer","volume":"29","author":"Cybulski","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","article-title":"Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel","volume":"121","author":"Tung","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0075","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0080","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5","article-title":"Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction","volume":"73","author":"Claus","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0085","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv124","article-title":"Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk","volume":"107","author":"Quante","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/1055-9965.EPI-12-0570","article-title":"Which risk model to use? Clinical implications of the ACS MRI screening guidelines","volume":"22","author":"Ozanne","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-148-5-200803040-00004","article-title":"Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model","volume":"148","author":"Tice","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.rcl.2010.06.012","article-title":"The use of breast imaging to screen women at high risk for cancer","volume":"48","author":"Sickles","year":"2010","journal-title":"Radiol. Clin. N. Am."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0110","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nature05887","article-title":"Genome-wide association study identifies novel breast cancer susceptibility loci","volume":"447","author":"Easton","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng.2563","article-title":"Large-scale genotyping identifies 41 new loci associated with breast cancer risk","volume":"45","author":"Michailidou","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ng.3242","article-title":"Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer","volume":"47","author":"Michailidou","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju397","article-title":"The contributions of breast density and common genetic variation to breast cancer risk","volume":"107","author":"Vachon","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0130","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0140","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-013-2540-z","article-title":"Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program","volume":"139","author":"Moller","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/djn440","article-title":"Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers","volume":"101","author":"Berrington de Gonzalez","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0150","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1200\/JCO.2009.27.2294","article-title":"BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study","volume":"28","author":"Rijnsburger","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0155","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw290","article-title":"Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial","volume":"109","author":"Shieh","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0165","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1001\/jama.2014.6095","article-title":"Breast cancer screening using tomosynthesis in combination with digital mammography","volume":"311","author":"Friedewald","year":"2014","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.ygyno.2017.04.013_bb0170","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1200\/JCO.2015.63.4147","article-title":"Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial","volume":"34","author":"Tagliafico","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0175","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jama.2012.388","article-title":"Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk","volume":"307","author":"Berg","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0180","doi-asserted-by":"crossref","first-page":"20160397","DOI":"10.1259\/bjr.20160397","article-title":"Adding the power of iodinated contrast media to the credibility of mammography in breast cancer diagnosis","volume":"89","author":"Tsigginou","year":"2016","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0185","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0190","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer\u201496-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0195","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0200","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0205","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0210","doi-asserted-by":"crossref","first-page":"698","DOI":"10.7326\/0003-4819-159-10-201311190-00718","article-title":"Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0215","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0220","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2010.33.0258","article-title":"Benefit\/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50years or older","volume":"29","author":"Freedman","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0225","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0230","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0235","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0240","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1399-0004.2008.01111.x","article-title":"Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention","volume":"75","author":"Cybulski","year":"2009","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0245","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0250","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","article-title":"Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic","volume":"14","author":"Heemskerk-Gerritsen","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0255","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers","volume":"28","author":"Kurian","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0260","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/M13-1684","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation","volume":"160","author":"Nelson","year":"2014","journal-title":"Ann. Intern. Med."},{"year":"2013","series-title":"Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer","key":"10.1016\/j.ygyno.2017.04.013_bb0265"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0270","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0275","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Graeser","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","article-title":"Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer","volume":"140","author":"Evans","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0285","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0290","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0295","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2006.06.3024","article-title":"Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation","volume":"25","author":"Schmidt","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0300","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"Eisen","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0305","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0310","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw177","article-title":"Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kotsopoulos","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0315","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0320","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0325","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0330","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1002\/cncr.26655","article-title":"Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer","volume":"118","author":"Hyman","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0335","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0340","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/annonc\/mdt068","article-title":"Outcome of BRCA1-compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands","volume":"24","author":"Vencken","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0345","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0350","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jnci\/djs494","article-title":"Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2","volume":"105","author":"McLaughlin","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0355","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Candido-dos-Reis","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0360","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2014.55.1713","article-title":"Prognosis and conditional disease-free survival among patients with ovarian cancer","volume":"32","author":"Kurta","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0365","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0370","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0375","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0380","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.27839","article-title":"The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1\/BRCA2 mutation carriers: implications for counseling","volume":"119","author":"Vencken","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0385","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cncr.27842","article-title":"Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer","volume":"119","author":"Domchek","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0390","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamasurg.2014.1081","article-title":"Breast cancer following ovarian cancer in BRCA mutation carriers","volume":"149","author":"Gangi","year":"2014","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001034","article-title":"Tamoxifen for relapse of ovarian cancer","author":"Williams","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0400","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","article-title":"Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients","volume":"13","author":"Smyth","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0405","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0410","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0415","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","article-title":"Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers","volume":"34","author":"Schmidt","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.013_bb0420","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1053\/gast.2000.20228","article-title":"Very high risk of cancer in familial Peutz-Jeghers syndrome","volume":"119","author":"Giardiello","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2017.04.013_bb0425","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2016.09.015","article-title":"The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - an analysis of NRG oncology\/gynecologic oncology group trials","volume":"143","author":"Chan","year":"2016","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817307941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817307941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:13:53Z","timestamp":1750205633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817307941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0090825817307941"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing hereditary breast cancer risk in women with and without ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}